Market Performance - The monkeypox concept sector declined by 0.86%, ranking among the top losers in the market, with stocks like Fuyuan Pharmaceutical and Chengyi Pharmaceutical hitting the daily limit down [1] - Notable declines were observed in Wanfu Biology, Rejing Biology, and Zhongsheng Pharmaceutical, while 23 stocks within the sector saw price increases, with Toukeng Life, Chuangyuan Technology, and New Industry leading the gains at 7.45%, 3.96%, and 1.86% respectively [1][2] Capital Flow - The monkeypox concept sector experienced a net outflow of 1.624 billion yuan, with 61 stocks facing net outflows, and 11 stocks seeing outflows exceeding 50 million yuan [2] - The stock with the highest net outflow was Hanyu Pharmaceutical, with a net outflow of 212.3 million yuan, followed by Fuyuan Pharmaceutical, Wanfu Biology, and Zhongsheng Pharmaceutical with net outflows of 164.1 million yuan, 126 million yuan, and 120 million yuan respectively [2][3] Top Gainers and Losers - The top gainers in the monkeypox concept sector included Toukeng Life, which saw a net inflow of 24.68 million yuan, and Guoyao Modern with a net inflow of 2.185 million yuan [4] - Conversely, the top losers included Hanyu Pharmaceutical, Fuyuan Pharmaceutical, and Wanfu Biology, which all faced significant capital outflows [2][3]

Group 1 - The fentanyl concept sector increased by 1.24%, ranking second in terms of sector gains, with one stock, Botao Bio, hitting a 20% limit up [1][2] - The main stocks in the fentanyl sector experienced mixed performance, with notable declines in Renfu Pharmaceutical, Oriental Bio, and Guoyao Modern, which fell by 3.16%, 2.59%, and 1.23% respectively [1][2] Group 2 - The fentanyl concept sector saw a net inflow of 50 million yuan, with four stocks receiving significant inflows, led by Botao Bio with a net inflow of 51.6459 million yuan [2][3] - The net inflow ratios for Botao Bio, Oriental Bio, and Wanfu Bio were 11.85%, 5.85%, and 5.04% respectively, indicating strong interest from main funds [3]

Core Insights - The animal vaccine sector saw a rise of 1.41%, ranking 8th among concept sectors, with 15 stocks increasing in value, led by Shenlian Bio, Kanghua Bio, and Tiankang Bio, which rose by 9.71%, 8.60%, and 2.02% respectively [1][2] - The sector experienced a net outflow of 6.53 million yuan in capital, with seven stocks receiving net inflows, primarily led by Guoyao Modern, which saw a net inflow of 29.79 million yuan [2][3] - The top three stocks by net inflow ratio were Guoyao Modern at 17.35%, Kexing Pharmaceutical at 9.18%, and Luoniushan at 9.02% [3] Stock Performance - Guoyao Modern had a daily increase of 1.35% with a turnover rate of 1.14% and a net capital flow of 29.79 million yuan [3] - Kexing Pharmaceutical increased by 0.54% with a turnover rate of 2.79% and a net capital flow of 24.08 million yuan [3] - Luoniushan rose by 1.11% with a turnover rate of 2.44% and a net capital flow of 16.07 million yuan [3] Declining Stocks - Xianfeng Holdings, Biotech Shares, and Yongshun Bio were among the stocks with the largest declines, falling by 3.05%, 1.04%, and 0.60% respectively [1][4] - Other notable declines included Tian Kang Bio at 2.02% and Ruipu Bio at 0.56% [4]

| 601139 | 深圳燃 | 0.92 | 0.30 | 6.57 | 6.61 | 0.63 | | --- | --- | --- | --- | --- | --- | --- | | | 气 | | | | | | | 002813 | 路畅科 | 1.36 | 2.69 | 24.37 | 24.52 | 0.63 | | | 技 | | | | | | | 000966 | 长源电 | 0.66 | 0.71 | 4.58 | 4.60 | 0.45 | | | 力 | | | | | | | 601158 | 重庆水 | 0.43 | 0.12 | 4.70 | 4.72 | 0.35 | | | 务 | | | | | | | 000875 | 吉电股 | 1.35 | 0.84 | 5.24 | 5.25 | 0.25 | | | 份 | | | | | | | 002032 | 苏泊尔 | 0.21 | 0.08 | 51.32 | 51.39 | 0.14 | | 002157 | 正邦科 | 0.70 | 0.38 | 2.87 | 2.87 | 0.12 | | | 技 | | ...

Market Overview - The Shanghai Composite Index is at 3636.69 points, slightly down by 0.08%, with a total trading volume of 802.9 billion yuan [1] - 21 A-shares have surpassed their annual line today, with notable stocks showing significant deviation rates [1] Stocks with Significant Deviation Rates - *ST Yitong has a deviation rate of 2.59%, with a price increase of 4.74% and a turnover rate of 2.93% [1] - Landun Optoelectronics shows a deviation rate of 1.97%, with a price increase of 6.14% and a turnover rate of 10.07% [1] - Guodian Power has a deviation rate of 1.53%, with a price increase of 1.52% and a turnover rate of 0.48% [1] Stocks with Smaller Deviation Rates - Pumen Technology and Jinlang Technology have just crossed the annual line with minor deviation rates of 0.06% and 0.13% respectively [2] - Longi Green Energy has a deviation rate of 0.20%, with a price increase of 0.25% [2]

Group 1: Company Performance - SMIC reported Q2 revenue of $2.21 billion, a 16% year-over-year increase, but a 1.7% decrease quarter-over-quarter [1] - China Mobile achieved a net profit of 84.2 billion yuan in the first half of 2025, a 5% year-over-year increase, with a mid-term dividend of 2.75 HKD per share, up 5.8% [2] - Huahong Semiconductor's Q2 revenue was $566.1 million, an 18.3% year-over-year increase, with Q3 revenue guidance of $620 million to $640 million [3] Group 2: Business Operations and Developments - Chuangzhong Technology clarified that it does not engage in the production of liquid-cooled servers, only participating in testing platforms, with no revenue generated from this segment in H1 2025 [4] - Shuo Beid announced it has sent samples of liquid-cooled server plates to Taiwanese clients, but the ability to pass testing and achieve mass production remains uncertain [5] - Furi Electronics stated that its subsidiary provides JDM/OEM services for service robots, but this revenue accounts for less than 1% of the company's total revenue [6] Group 3: Industry Trends and Market Movements - Sales of new energy vehicles by Seres reached 44,581 units in July, reflecting a 5.7% year-over-year increase [7] - Longyuan Power completed a power generation of 6,328.76 MWh in July, marking a 2.44% year-over-year growth [8] - Jianglong Shipbuilding won a bid for the "Blue Granary" marine economic development project, indicating ongoing infrastructure investments [8]

Group 1 - The core point of the article is that China National Pharmaceutical Group Modern has received approval from the National Medical Products Administration for the marketing application of the raw material drug ketamine hydrochloride [1] Group 2 - The approval was granted to the wholly-owned subsidiary of the company, China National Pharmaceutical Group Industrial Co., Ltd. [1] - The announcement was made on the evening of August 7 [1]

证券代码：600420 证券简称：国药现代 公告编号：2025-061 上海现代制药股份有限公司 关于全资子公司获得化学原料药上市申请批准通知书 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，上海现代制药股份有限公司（以下简称公司）全资子公司国药集团工 业有限公司（以下简称国药工业）收到国家药品监督管理局核准签发的《化学原 料药上市申请批准通知书》，批准原料药盐酸氯胺酮上市申请，现将相关情况公 告如下： 一、化学原料药基本信息 化学原料药名称：盐酸氯胺酮 登记号：Y20240000546 通知书编号：2025YS00674 化学原料药注册标准编号：YBY67872025 包装规格：1.5kg/桶、2kg/桶、4.5kg/桶 生产企业：国药集团工业有限公司廊坊分公司 企业地址：廊坊经济技术开发区创业路 申请事项：境内生产化学原料药上市申请 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。 二、子公司信息 1、公司名称：国药集团工业有限公司 注册地址：北京市顺义 ...

盐酸氯胺酮制剂是一种静脉麻醉药，可作为单一麻醉剂用于无需骨骼肌松弛的诊断和外科手术，也可用 于诱导全身麻醉或者作为其他麻醉剂的补充。 智通财经APP讯，国药现代(600420.SH)发布公告，近日，公司全资子公司国药集团工业有限公司(简称 国药工业)收到国家药品监督管理局核准签发的《化学原料药上市申请批准通知书》，批准原料药盐酸 氯胺酮上市申请。 ...

Group 1 - The core point of the article is that China National Pharmaceutical Group Modern has received approval from the National Medical Products Administration for the market application of the raw material drug ketamine hydrochloride [1] - Ketamine hydrochloride is a intravenous anesthetic that can be used as a sole anesthetic for diagnostic and surgical procedures without muscle relaxation, and can also be used for inducing general anesthesia or as a supplement to other anesthetics [1] - The cumulative R&D investment by China National Pharmaceutical Group Industrial for this project is approximately 7.521 million yuan [1] Group 2 - Other domestic companies with registered status "A" for ketamine hydrochloride raw materials include Anhui Wanhe Pharmaceutical Co., Ltd. and Jiangsu Hengrui Medicine Co., Ltd. [1]